Our findings align with the aforementioned observations, as the BNT162b2 booster results in an increase in IgG and IgA S1-RBD antibodies compared to CoronaVac (2x), including individuals who have recovered from COVID-19 but were not vaccinated and pre-pandemic sera (15, 16). The gene discussed is CD79A; the disease is COVID-19.